Retrospective Study Open Access
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2014; 20(34): 12241-12248
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.12241
Downregulation of miR-193a-5p correlates with lymph node metastasis and poor prognosis in colorectal cancer
Peng Zhang, Deng-Bo Ji, Chang-Zheng Du, Jin Gu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Colorectal Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, China
Hai-Bo Han, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cell Biology, Peking University Cancer Hospital and Institute, Beijing 100142, China
Yun-Fei Shi, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing 100142, China
Author contributions: Zhang P and Gu J designed the research; Zhang P, Ji DB, Han HB, Shi YF and Du CZ performed the research; Zhang P analyzed the data and wrote the paper; Gu J made critical revisions of the manuscript.
Supported by National Natural Science Foundation of China, No. 30872467, No. 81030040, No. 81201965 and No. 81372593; Beijing Natural Science Foundation, No. 7132052; and the National High Technology Research and Development Program of China (863 Program), No. 2012AA02A506
Correspondence to: Jin Gu, MD, FACS, Professor, Chairman, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Colorectal Surgery, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. zlgujin@126.com
Telephone: +86-10-88141032 Fax: +86-10-88141032
Received: March 14, 2014
Revised: May 8, 2014
Accepted: May 29, 2014
Published online: September 14, 2014

Abstract

AIM: To investigate the correlation of miR-193a-5p with lymph node metastasis and postoperative survival of colorectal cancer (CRC) patients.

METHODS: A total of 304 formalin-fixed, paraffin-embedded specimens (69 paired cancer and normal tissues, 55 primary tumors of stage III CRC and matched lymph nodes, and 56 primary tumors of stage II CRC) were included in this study. The relative expression levels of miR-193a-5p in the normal mucosa, primary cancer, and metastatic lymph node lesions were measured by quantitative real-time reverse transcriptase polymerase chain reaction. We evaluated the association of its expression with colorectal cancer lymph node metastasis, clinicopathological factors, and patient survival.

RESULTS: The relative expression level of miR-193a-5p was significantly lower in CRC tissues than in the normal mucosa (P = 0.0060). The expression levels of miR-193a-5p were lower in primary CRC tissues with lymph node metastases than in those without metastases (P = 0.0006), and decreased expression of miR-193a-5p correlated with advanced lymph node metastatic stage (P = 0.0007). Kaplan-Meier analysis showed that patients with low miR-193a-5p expression had decreased disease-free survival (DFS) (P = 0.0026) and poor overall survival (OS) (P = 0.0003). Interestingly, for the group of patients with lymph node metastases, miR-193a-5p expression was also related to survival. Patients with low miR-193a-5p expression had decreased DFS (P = 0.0262) and poor OS (P = 0.0230). Moreover, multivariate analysis indicated that downregulation of miR-193a-5p was an independent predictor of poor OS.

CONCLUSION: Downregulation of miR-193a-5p correlates with lymph node metastasis and poor survival of CRC. miR-193a-5p may be a useful biomarker for CRC diagnosis, metastasis and prognosis prediction.

Key Words: miR-193a-5p, Colorectal cancer, Lymph node metastasis, Prognosis, Biomarker

Core tip: We determined the expression of miR-193a-5p in colorectal cancer (CRC) tissues and metastatic lesions in the lymph nodes using quantitative real-time reverse transcriptase polymerase chain reaction. Downregulation of miR-193a-5p correlated with tumor progression, lymph node metastasis and poor survival in CRC patients. These findings suggest that miR-193a-5p could be used as a molecular biomarker of diagnosis, early-stage metastasis prediction, and prognosis forecast for CRC. This is believed to be the first study to investigate the relationship between miR-193a-5p expression and lymph node metastasis in CRC.



INTRODUCTION

Colorectal cancer (CRC) is one of the three leading causes of cancer-related death worldwide, with approximately 1200000 new cases and 600000 deaths annually[1]. In China, the incidence and mortality from CRC have increased rapidly in the past several decades[2], with death generally resulting from tumor recurrence or metastasis[3]. Metastasis to regional lymph nodes plays a critical role in CRC tumor progression; it affects prognosis[4], and occurs commonly in early-stage metastasis. Moreover, lymph node involvement often promotes further hematogenous metastasis[5]. After radical surgery, the 5-year survival rate of patients with early-stage CRC is > 90%, but the 5-year survival rate of advanced-stage patients is < 10%[6]. Although some genes related to lymph node metastasis have been reported, the molecular mechanisms of early-stage metastasis in CRC are still unclear[7-9]. Thus, identification of biomarkers associated with lymph node metastasis of CRC will benefit clinical evaluation.

MicroRNAs are a class of small noncoding RNA molecules that function by targeting 3’-untranslated regions[10], thus altering gene expression. It has been reported that they are involved in various biological processes, including differentiation and tumorigenesis[11]. Some studies have demonstrated that miRNAs also participate in lymph node metastasis of human cancer[12-15]. As a member of the miR-193 family, miR-193a plays a critical role in cancer progression. In general, its expression has been reported to decrease in human cancers, and its downregulation correlates with advanced progression[16,17]. A recent study reported downregulation of miR-193a-5p expression in an advanced human CRC cell line SW620 established from a metastatic lymph node[18], and it showed that miR-193a-5p may participate in lymph node metastasis of CRC. However, correlative studies following the expression of miR-193a-5p in CRC tissues or metastatic lymph node lesions (MLNLs) have not been reported.

In this study, we investigated the expression of miR-193a-5p in CRC tissues, normal mucosa and MLNLs, and analyzed the association of its expression with lymph node metastasis and clinical prognosis.

MATERIALS AND METHODS
Specimens and clinical data collection

It was difficult to obtain blood samples from the patients, so we chose formalin-fixed, paraffin-embedded (FFPE) specimens for this study. A total of 304 FFPE specimens, including 69 paired cancer and normal tissues, 55 primary tumors of stage III CRC and matched lymph nodes, and 56 primary tumors of stage II CRC, were collected from 111 patients who underwent surgical resection at Beijing Cancer Hospital between January 2006 and October 2007. Patients did not receive any preoperative treatment, in particular, radiotherapy or chemotherapy. After excision, tissue specimens were sectioned for subsequent analysis. The samples were stained with hematoxylin and eosin and examined histopathologically. Sections containing > 90% carcinoma cells were used to prepare total RNA. Complete clinicopathological data were collected for each patient. All patients signed informed consent forms. This study was approved by the Medical Ethics Committee of Beijing Cancer Hospital.

Real-time quantitative reverse transcriptase polymerase chain reaction

Total RNA was extracted from cancer tissues, normal mucosa and paired lymph nodes using the miRNeasy FFPE Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. For real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), we used TaqMan Reverse Transcription Reagents followed by PCR Master Mix (Haoqin Biotechnology, Shanghai, China). All reactions were run in triplicate on an ABI7500 PCR machine using miR-193a-5p specific primers (Haoqin Biotechnology). Following an initial denaturation at 95 °C for 10 min, real-time qRT-PCR cycling parameters included 40 cycles of denaturation at 95 °C for 15 s, annealing at 57 °C for 30 s, and final extension at 72 °C for 30 s. The comparative cycle threshold (Ct) method was used to calculate the expression levels of miR-193a-5p, and U6 small nuclear RNA was used as an internal reference. The relative expression of miR-193a-5p to U6 was determined using the equation 2-ΔCt, where ΔCt = CtmiR-193a-5p-CtU6[19].

Statistical analysis

miR-193a-5p expression in CRC was compared with expression in normal mucosa or lymph nodes using the Mann-Whitney test (for two groups) or the Kruskal-Wallis test (for more than two groups). Measurement data were analyzed using Student’s t test, while categorical data were studied using the χ2 test. We analyzed the postoperative survival rate using the Kaplan-Meier method and performed a log-rank test to assess the differences in survival rates. Multivariate analysis was performed using a Cox regression model. SPSS version 13.0 (SPSS, Chicago, IL, United States) was used for all statistical analyses. We used two-sided P values and considered < 0.05 to be statistically significant.

RESULTS
Expression of miR-193a-5p decreases in primary CRC

To test the effect of miR-193a-5p on tumor progression, the expression levels of miR-193a-5p were measured in cancer tissues and paired normal tissues from 69 patients with CRC. As shown in Figure 1A, miR-193a-5p expression was significantly decreased in cancer tissues to 40% of that in the matched normal mucosa (P = 0.0060). These data suggest that miR-193a-5p functions as a tumor suppressor to prevent progression of CRC.

Figure 1
Figure 1 Expression level of miR-193a-5p in colorectal cancer, metastatic lymph node and normal tissues. A: Comparison of miR-193a-5p expression between colorectal cancer and normal mucosa in 69 paired samples. miR-193a-5p expression levels were higher in normal tissues than in cancer tissues (P = 0.0060); B: Comparison of miR-193a-5p expression in primary colorectal cancer (CRC) tissue with and without lymph node metastasis. miR-193a-5p expression levels were significantly lower in primary CRC with lymph node metastasis than without lymph node metastasis (P = 0.0006); C: Correlation of miR-193a-5p expression in primary CRC with lymph node stage (N0/N1/N2). Decreased expression of miR-193a-5p was associated with advanced lymph node stage (P = 0.0007); D: Association of miR-193a-5p expression in colorectal cancer with paired metastatic lymph nodes. No significant difference of miR-193a-5p expression was observed between colorectal cancer and paired metastatic lymph nodes (P = 0.9321). N: Lymph node stage; N0: Stage N0; N1: Stage N1; N2: Stage N2.
Expression of miR-193a-5p decreases with early-stage metastasis and with advanced lymph node metastatic stage

To determine the association of miR-193a-5p with early-stage metastasis, we analyzed the expression level of miR-193a-5p in primary CRC with and without lymph node metastasis. As shown in Figure 1B, miR-193a-5p expression levels in primary CRC tissues with lymph node metastasis were significantly decreased to 40% of those without metastasis (P = 0.0006). In addition, downregulation of miR-193a-5p significantly correlated with increasing lymph node stage. miR-193a-5p expression decreased progressively, from 100% (stage N0) to 60% (stage N1) and 30% (stage N2) (P = 0.0007) (Figure 1C). These data indicated that low expression of miR-193a-5p was associated with lymph node metastasis in CRC. We also quantified the expression levels of miR-193a-5p in MLNLs, but found no significant differences between primary cancer tissues and MLNLs (P = 0.9321) (Figure 1D).

Decreased expression of miR-193a-5p correlates with venous invasion and lymph node metastasis

To evaluate the relationship between expression levels of miR-193a-5p and clinicopathological factors of CRC, we classified its expression as low or high according to the median value. As shown in Table 1, the data indicated that decreased expression of miR-193a-5p was significantly associated with venous invasion (P = 0.008) and lymph node metastasis (P < 0.001) (Table 1). These data indicated that downregulation of miR-193a-5p was associated with malignant behavior of CRC.

Table 1 Correlation between miR-193a-5p expression and clinicopathological factors of colorectal cancer.
VariablemiR-193a-5p expression
P value
Low (n = 56)High (n = 55)
Age (yr)61.9 ± 13.962.3 ± 11.90.298
Gender0.924
Male2828
Female2827
Tumor size0.768
≤ 5 cm2624
> 5 cm3031
Degree of differentiation0.053
Well and moderate3846
Poor189
Venous invasion0.008b
Negative4352
Positive133
Depth of invasion0.484
T1, T21211
T3, T44444
Lymph node metastasis< 0.001b
Absent1937
Present3718
Location0.921
Colon2726
Rectum2929
Downregulation of miR-193a-5p is associated with poor prognosis of CRC patients

To assess the correlation of miR-193a-5p with prognosis of CRC patients, we plotted disease-free survival (DFS) and overall survival (OS) curves using the Kaplan-Meier method. As shown in Figure 2, the DFS and OS rates were significantly lower in patients with low miR-193a-5p expression than in those with high miR-193a-5p expression (P = 0.0026, P = 0.0003, respectively). A similar result was found in the group of patients with lymph node metastases. The DFS and OS rates were significantly lower in patients with low miR-193a-5p expression than in those with high miR-193a-5p expression (P = 0.0262, P = 0.0230, respectively). Using univariate analysis of the Cox regression model, we identified four prognostic factors that had statistical significance: depth of invasion (P = 0.009), venous invasion (P < 0.001), lymph node metastasis (P < 0.001), and miR-193a-5p expression levels (P = 0.004) (Table 2). Moreover, multivariate analysis indicated that three of these prognostic factors were also independent predictors of poor survival in colorectal cancer: low miR-193a-5p expression levels (log-rank test, P = 0.031), increased depth of invasion (log-rank test, P = 0.036), and lymph node metastasis (log-rank test, P < 0.001) (Table 3). Together, these data indicated that downregulation of miR-193a-5p was correlated with lymph node metastasis and poor survival.

Table 2 Univariate analysis of clinicopathological factors for overall survival of colorectal cancer patients.
VariableCasesHR95%CIP value
Gender0.582-1.8740.885
Male561
Female551.004
Age (yr)0.820-2.7380.189
≤ 60511
< 60601.498
Tumor size0.921-3.1240.090
≤ 5 cm501
> 5 cm611.696
Differentiation0.852-3.0980.140
Well, moderate841
Poor271.625
Venous invasion2.058-7.781< 0.001b
Negative951
Positive164.002
Depth of invasion1.494-15.5890.009b
T1, T2231
T3, T4884.826
Location0.673-1.9450.619
Rectum581
Colon531.144
Lymph node metastasis3.194-13.937< 0.001b
Absent561
Present556.672
miR-193a-5p expression1.340-4.6530.004b
High551
Low562.497
Figure 2
Figure 2 Kaplan-Meier survival curves of patients with colorectal cancer based on miR-193a-5p expression. A: Kaplan-Meier disease free survival curves of patients with colorectal cancer (CRC) based on miR-193a-5p expression. Patients in the low expression group had significantly lower disease free survival rates than those in the high expression group (log-rank test, P = 0.0026); B: Kaplan-Meier overall survival curves of patients with CRC based on miR-193a-5p expression. Patients in the low expression group had significantly lower overall survival rates than those in the high expression group (log-rank test, P = 0.0003); C: Kaplan-Meier disease free survival curves of patients with lymph node metastases based on miR-193a-5p expression. Patients in the low expression group had significantly lower disease free survival rates than those in high expression group (log-rank test, P = 0.0262); D: Kaplan-Meier overall survival curves of patients with lymph node metastases based on miR-193a-5p expression. Patients in the low expression group had significantly lower overall survival rates than those in high expression group (log-rank test, P = 0.0230). N: Lymph node stage; N0: Stage N0; N1: Stage N1; N2: Stage N2.
Table 3 Multivariate analysis of clinicopathological factors for overall survival of colorectal cancer patients.
VariableCasesHR95%CIP value
Venous invasion0.799-3.2300.183
Negative951
Positive161.607
Depth of invasion1.087-11.7930.036a
T1, T2231
T3, T4883.58
Lymph node metastasis1.906-9.319< 0.001b
Absent561
Present554.214
miR-193a-5p expression1.070-3.9930.031a
High551
Low562.067
DISCUSSION

A growing number of studies have shown that miRNAs are involved in tumor progression and carcinogenesis[20-22], and in recent years, there has been an increased focus on miR-193a. Some researchers have reported the downregulation of miR-193a in tumor tissues, with the suggestion that it functions as a tumor suppressor[17,23-26]. In agreement with these studies, we found that the expression of miR-193a-5p decreased in primary CRC relative to normal tissues, suggesting that decreased miR-193a-5p expression may correlate with tumor progression and carcinogenesis of CRC.

In contrast, several studies have reported higher expression of miR-193a in tumor cells[27,28]. This inconsistency may be explained by the variation in molecular pathways that exist in different types of cancer tissues. In addition, Yong et al[29] found upregulation of miR-193a expression levels in the blood samples compared with the cancer tissues of CRC patients. The different results are probably due to the different study design. Another reason could be the effect of local tumor microenvironment. It is well known that miRNAs modulate the tumor microenvironment via a variety of signaling networks[30-32], but in addition, the microenvironment may also exert some effect on miRNA expression. Cismasiu et al[33] reported that expression of miR-193 varies by the location of stromal cells, being more specific in blood vessels compared with other cells. We think that the influence of stromal signaling may affect miR-193a expression in cancer tissues and blood.

Recent findings have shown that the varied expression of several miRNAs correlates with CRC lymph node metastasis and prognosis, and that they may be useful as novel biomarkers for clinical prediction of early-stage metastasis and prognosis[15,34,35]. Another finding, indicating that decreased expression of miR-193a-5p correlates with early metastasis in other cancer systems[18], suggests that miR-193a-5p is involved in early-stage metastasis of CRC. In this study, we quantified the expression of miR-193a-5p in primary CRC tissues. Our results demonstrated that miR-193a-5p expression was significantly downregulated in cancer tissues with positive lymph nodes relative to those with negative lymph nodes. These findings suggest that downregulation of miR-193a-5p correlates with lymph node metastasis of CRC and support the previous study of Yu et al[26]. He reported that miR-193a-3p and -5p could suppress metastasis in humans. In addition, we also investigated the expression of miR-193a-5p in MLNLs of CRC, but found no significant difference in expression between these and primary cancer tissues. These results indicate that the cancer cells in MLNLs came from the primary cancer lesions and had the same aggressive properties as the primary tumor.

We assessed the correlation between miR-193a-5p expression and clinicopathological factors and prognosis. Our results indicated that miR-193a-5p low expression was associated with venous invasion and lymph node metastasis, suggesting that miR-193a-5p is involved in the progression and early-stage metastasis of CRC. Moreover, using Kaplan-Meier survival curves, we demonstrated that higher miR-193a-5p expression was significantly correlated with increased DFS and OS of patients with CRC postoperatively. Conversely, lower miR-193a-5p expression was associated with poor OS, indicating that low miR-193a-5p expression level may be useful as a marker of poor prognosis in CRC. In addition, we analyzed several clinicopathological factors by the Cox regression method. These results showed that miR-193a-5p is an independent prognostic indicator, suggesting that it could serve as a novel molecular marker of early-stage metastasis and prognosis for patients with CRC. By identifying patients who are at higher risk for early-stage metastasis and have a poor prognosis, they may be screened and followed closely.

The exact molecular mechanisms of miR-193a-5p involvement in early-stage metastasis of CRC have not been elucidated. In some studies, miR-193a-5p has been shown to inhibit tumor cell proliferation and transformation[36,37]. It was recently reported that miR-193a-5p suppresses tumor cell activity by targeting the transforming growth factor (TGF), Wnt and mitogen-activated protein kinase pathways[16]. Another study found that TGF promotes the progression of prostatic carcinoma by modulating p53 and YY1[38]. Other studies have shown that YY1 improves tumor cell growth of CRC by inhibiting p53 and activating the Wnt pathway[39]. More recently, Schwitalla et al[40] have found that loss of p53 in enterocytes enables invasion and lymph node metastasis of colorectal tumors. We conjecture that miR-193a-5p may inhibit tumorigenesis and lymph node metastasis of CRC by targeting TGF and/or p53 and regulating YY1 expression by inactivation of the Wnt pathway. This may help to explain the downregulation of miR-193a-5p in primary CRC tissues with lymph node metastasis in the current study. The role of TGF in tumor progression is a double-edged sword and its function may depend on cancer progression[41-43]. This may partly explain the discordance of tumorigenic and anti-tumor roles of miR-193. We are planning additional studies to identify more precisely the molecular mechanisms of miR-193a-5p involvement in lymph node metastasis of CRC.

In conclusion, our studies confirm that miR-193a-5p expression is downregulated in CRC. In addition, downregulation of miR-193a-5p is correlated with lymph node metastasis and poor prognosis. We also found that miR-193a-5p is an independent prognostic factor. Identification is economically feasible if it is applied clinically to CRC patients because just a trace of total RNA can be tested for miR-193a-5p. Together, these results suggest that miR-193a-5p is a useful novel biomarker of early-stage metastasis diagnosis and prognosis, and a promising therapeutic target in the treatment of CRC.

COMMENTS
Background

Colorectal cancer (CRC) is one of the three leading causes of cancer-related death worldwide. In general, patients die from tumor recurrence or metastasis. Metastasis to regional lymph nodes plays a critical role in CRC progression and occurs commonly in early-stage metastasis. MicroRNAs are a class of small noncoding RNA molecules that are involved in various biological processes, including tumorigenesis. Some studies have demonstrated that miRNAs also participate in lymph node metastasis of human cancer. A recent study has shown that miR-193a-5p may participate in lymph node metastasis of CRC. However, correlative studies following the expression of miR-193a-5p in CRC tissues or metastatic lymph node lesions (MLNLs) have not been reported.

Research frontiers

Various studies have shown that miRNAs may be involved in lymph node metastasis of CRC. Although they analyzed their correlation with lymph node metastasis as a clinicopathological factor, no prior study has investigated miRNA expression in MLNLs. Although miR-193a-5p has shown variant expression in an advanced human CRC cell line SW620 established from a metastatic lymph node, no further study has been conducted.

Innovations and breakthroughs

In this study, the authors found that downregulation of miR-193a-5p was correlated with tumor progression, lymph node metastasis and poor survival of CRC patients. The findings of the study are novel and of clinical significance. It is a promising strategy to use miR-193a-5p as a molecular biomarker for diagnosis, early-stage metastasis prediction, and prognosis forecast for CRC.

Applications

The authors found that low expression of miR-193a-5p was associated with lymph node metastasis and poor prognosis of CRC patients. Therefore, by identifying patients who are at higher risk for early-stage metastasis and who have poor prognosis, they may be screened and followed closely. This study could provide a clue for clinical application of miRNAs to prevent early metastasis, resulting in good outcomes for CRC patients.

Terminology

U6 is one of the small nuclear ribonucleic acids (snRNAs); it is also commonly referred to as U-RNA and often is used as an internal reference to normalize miRNA expression because of its stable expression. Tumor microenvironment is the cellular environment in which the tumor exists, including surrounding blood vessels, immune cells, fibroblasts, other cells, signaling molecules, and the extracellular matrix. As mentioned in discussion, different components of the tumor microenvironment interact with miR-193a-5p and further induce its variant expression.

Peer review

In this manuscript, the authors examined the expression of miR-193a-5p in colorectal cancer tissues and the metastatic lymph node using quantitative polymerase chain reaction. It was found that down-regulation of miR-193a-5p correlated with tumor progression, lymph node metastasis and poor survival in CRC patients. The manuscript is nicely written and the study design is well constructed. The topic is innovative and of future clinical value and is indeed within the scope of the journal. This article may open the door wide for the future use of miR-193a-5p as a molecular biomarker for diagnosis and prognosis in colorectal cancer patients.

Footnotes

P- Reviewer: de Bree E, Kumai T, Meshikhes AWN, Shen J S- Editor: Ma YJ L- Editor: Logan S E- Editor: Ma S

References
1.  Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23762]  [Cited by in F6Publishing: 25159]  [Article Influence: 1935.3]  [Reference Citation Analysis (3)]
2.  Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118-126.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 680]  [Cited by in F6Publishing: 720]  [Article Influence: 51.4]  [Reference Citation Analysis (0)]
3.  Gutman M, Fidler IJ. Biology of human colon cancer metastasis. World J Surg. 1995;19:226-234.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Sasaki H, Miura K, Horii A, Kaneko N, Fujibuchi W, Kiseleva L, Gu Z, Murata Y, Karasawa H, Mizoi T. Orthotopic implantation mouse model and cDNA microarray analysis indicates several genes potentially involved in lymph node metastasis of colorectal cancer. Cancer Sci. 2008;99:711-719.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 38]  [Cited by in F6Publishing: 39]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
5.  Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res. 2000;157:55-81.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Xu N, Qiu H, Ding Y. [The relation between DNA replication error and clinicopathological features of colorectal carcinoma]. Zhonghua Bing Li Xue Zazhi. 1998;27:359-361.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Lin Y, Buckhaults PJ, Lee JR, Xiong H, Farrell C, Podolsky RH, Schade RR, Dynan WS. Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer. Neoplasia. 2009;11:864-873.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Akagi T, Hijiya N, Inomata M, Shiraishi N, Moriyama M, Kitano S. Visinin-like protein-1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients. Int J Cancer. 2012;131:1307-1317.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 11]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
9.  Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A, Kusunoki M. Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2013;34:2548-2557.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 83]  [Cited by in F6Publishing: 104]  [Article Influence: 9.5]  [Reference Citation Analysis (0)]
10.  Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853-858.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-269.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PA, Dötsch V, Kehrloesser S, Sayan BS. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA. 2012;109:15312-15317.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Liu B, Wu X, Liu B, Wang C, Liu Y, Zhou Q, Xu K. MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta. 2012;1822:1692-1704.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 126]  [Cited by in F6Publishing: 143]  [Article Influence: 11.9]  [Reference Citation Analysis (0)]
14.  Wang K, Li J, Guo H, Xu X, Xiong G, Guan X, Liu B, Li J, Chen X, Yang K. MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis. 2012;33:2147-2154.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 43]  [Cited by in F6Publishing: 52]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
15.  Wang X, Wang J, Ma H, Zhang J, Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol. 2012;29:919-927.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 87]  [Cited by in F6Publishing: 104]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
16.  Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, Alberti L. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 2011;129:680-690.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 106]  [Cited by in F6Publishing: 115]  [Article Influence: 8.2]  [Reference Citation Analysis (0)]
17.  Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL, Perälä M. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol. 2014;8:93-104.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 121]  [Cited by in F6Publishing: 136]  [Article Influence: 12.4]  [Reference Citation Analysis (0)]
18.  Liu X, Zhang Z, Sun L, Chai N, Tang S, Jin J, Hu H, Nie Y, Wang X, Wu K. MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis. 2011;32:1798-1805.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 106]  [Cited by in F6Publishing: 121]  [Article Influence: 9.3]  [Reference Citation Analysis (0)]
19.  Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005;353:1768-1771.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682-688.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147-152.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1441]  [Cited by in F6Publishing: 1456]  [Article Influence: 91.0]  [Reference Citation Analysis (0)]
23.  Yang Y, Zhou L, Lu L, Wang L, Li X, Jiang P, Chan LK, Zhang T, Yu J, Kwong J. A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma. Oncogene. 2013;32:3432-3442.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 52]  [Cited by in F6Publishing: 59]  [Article Influence: 4.9]  [Reference Citation Analysis (0)]
24.  Yang Y, Li X, Yang Q, Wang X, Zhou Y, Jiang T, Ma Q, Wang YJ. The role of microRNA in human lung squamous cell carcinoma. Cancer Genet Cytogenet. 2010;200:127-133.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 66]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
25.  Kwon JE, Kim BY, Kwak SY, Bae IH, Han YH. Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1. Apoptosis. 2013;18:896-909.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 76]  [Cited by in F6Publishing: 83]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
26.  Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F. MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene. 2014;Jan 27; Epub ahead of print.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 186]  [Cited by in F6Publishing: 206]  [Article Influence: 20.6]  [Reference Citation Analysis (0)]
27.  Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest. 2011;121:809-820.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 58]  [Cited by in F6Publishing: 64]  [Article Influence: 4.9]  [Reference Citation Analysis (0)]
28.  Wang W, Corrigan-Cummins M, Hudson J, Maric I, Simakova O, Neelapu SS, Kwak LW, Janik JE, Gause B, Jaffe ES. MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica. 2012;97:586-594.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 85]  [Cited by in F6Publishing: 92]  [Article Influence: 7.1]  [Reference Citation Analysis (0)]
29.  Yong FL, Law CW, Wang CW. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer. 2013;13:280.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 127]  [Cited by in F6Publishing: 143]  [Article Influence: 13.0]  [Reference Citation Analysis (0)]
30.  Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol. 2012;14:159-167.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 209]  [Cited by in F6Publishing: 256]  [Article Influence: 19.7]  [Reference Citation Analysis (0)]
31.  Bronisz A, Wang Y, Nowicki MO, Peruzzi P, Ansari KI, Ogawa D, Balaj L, De Rienzo G, Mineo M, Nakano I. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1. Cancer Res. 2014;74:738-750.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 171]  [Cited by in F6Publishing: 177]  [Article Influence: 16.1]  [Reference Citation Analysis (0)]
32.  Melo SA, Kalluri R. miR-29b moulds the tumour microenvironment to repress metastasis. Nat Cell Biol. 2013;15:139-140.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 39]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
33.  Cismasiu VB, Radu E, Popescu LM. miR-193 expression differentiates telocytes from other stromal cells. J Cell Mol Med. 2011;15:1071-1074.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 96]  [Cited by in F6Publishing: 97]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
34.  Zhou T, Zhang G, Liu Z, Xia S, Tian H. Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Colorectal Dis. 2013;28:19-24.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 67]  [Cited by in F6Publishing: 79]  [Article Influence: 7.2]  [Reference Citation Analysis (0)]
35.  Li J, Du L, Yang Y, Wang C, Liu H, Wang L, Zhang X, Li W, Zheng G, Dong Z. MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2. Cancer Lett. 2013;329:84-90.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 94]  [Cited by in F6Publishing: 105]  [Article Influence: 8.8]  [Reference Citation Analysis (0)]
36.  Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W, Kang HY, Yan GT, Wang LL, Yu L. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene. 2011;30:3416-3428.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 121]  [Cited by in F6Publishing: 123]  [Article Influence: 9.5]  [Reference Citation Analysis (0)]
37.  Iliopoulos D, Rotem A, Struhl K. Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res. 2011;71:5144-5153.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 69]  [Cited by in F6Publishing: 71]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
38.  Caggia S, Libra M, Malaponte G, Cardile V. Modulation of YY1 and p53 expression by transforming growth factor-β3 in prostate cell lines. Cytokine. 2011;56:403-410.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 10]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
39.  Zhang N, Li X, Wu CW, Dong Y, Cai M, Mok MT, Wang H, Chen J, Ng SS, Chen M. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene. 2013;32:5078-5088.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 140]  [Cited by in F6Publishing: 159]  [Article Influence: 13.3]  [Reference Citation Analysis (0)]
40.  Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, Lechel A, Rudolph KL, Langer R, Slotta-Huspenina J. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell. 2013;23:93-106.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 204]  [Cited by in F6Publishing: 209]  [Article Influence: 19.0]  [Reference Citation Analysis (0)]
41.  Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol. 1998;8:1243-1252.  [PubMed]  [DOI]  [Cited in This Article: ]
42.  Qin J, Wu SP, Creighton CJ, Dai F, Xie X, Cheng CM, Frolov A, Ayala G, Lin X, Feng XH. COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature. 2013;493:236-240.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 122]  [Cited by in F6Publishing: 139]  [Article Influence: 11.6]  [Reference Citation Analysis (0)]
43.  Wang X, Abraham S, McKenzie JA, Jeffs N, Swire M, Tripathi VB, Luhmann UF, Lange CA, Zhai Z, Arthur HM. LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature. 2013;499:306-311.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 365]  [Cited by in F6Publishing: 345]  [Article Influence: 31.4]  [Reference Citation Analysis (0)]